Insights on Drug Levels and Non-Sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy

被引：0
|
作者：
Gutierrez, Felix [1 ,2 ,3 ]
Fernandez-Gonzalez, Marta [1 ,3 ]
Ledesma, Christian [1 ]
Losada-Echeberria, Maria [4 ]
Barrajon-Catalan, Enrique [4 ]
Masia, Mar [1 ,2 ,3 ]
机构：
[1] Hosp Gen Univ Elche, Infect Dis Unit, Elche, Spain
[2] Univ Miguel Hernandez, Dept Clin Med, Avda Univ S-N, Alicante 03202, Spain
[3] Inst Salud Carlos III, CIBERINFEC, Madrid, Spain
[4] Univ Miguel Hernandez, Inst Res Dev & Innovat Hlth Biotechnol Elche IDiBE, Elche, Spain
来源：
CLINICAL INFECTIOUS DISEASES | 2025年
关键词：
D O I：
10.1093/cid/ciae617
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Long-acting cabotegravir/rilpivirine as a safe antiretroviral therapy in solid organ transplanted HIV patients
    Moreno, Ana
    Del Campo, Santos
    Jesus Perez-Elias, Maria
    Luis Casado, Jose
    Garcia, Miguel
    Velez, Manuel
    Jesus Vivancos, Maria
    Moreno, Santiago
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 82 - 82
  • [22] What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?
    Bettonte, Sara
    Berton, Mattia
    Marzolini, Catia
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (05) : 243 - 247
  • [23] Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirine
    Fernandez, Analuz
    Scevola, Sofia
    Niubo, Jordi
    Sykes, Craig
    Schauer, Amanda P.
    Piatti, Camila
    Morenilla, Sandra
    Sedo, Alicia
    Soriano, Irene
    Garcia, Benito
    Medina, Daniel
    Tiraboschi, Juan
    Saumoy, Maria
    Cottrell, Mackenzie L.
    Imaz, Arkaitz
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 3 - 4
  • [24] Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report
    Sunagawa, Shawnalyn W.
    Havens, Joshua P.
    Podany, Anthony
    Walker, Bryan
    Scarsi, Kimberly K.
    Bares, Sara H.
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (12):
  • [25] Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine
    Mazzitelli, Maria
    Avolio, Antonio
    Carandina, Riccardo
    Parisi, Saverio
    Wensing, Annemarie
    Cattelan, Annamaria
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (08) : 2074 - 2076
  • [26] Long-acting antiretroviral therapy in the context of viral suppression
    Ring, Kyle
    Orkin, Chloe
    CURRENT OPINION IN HIV AND AIDS, 2025, 20 (01) : 4 - 10
  • [27] Virological failure rate and emergent resistance in real-world studies evaluating long-acting cabotegravir and rilpivirine in people with baseline viral suppression
    Smuk, Melanie
    Elias, Alexa
    Ring, Kyle
    Orkin, Chloe
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 97 - 98
  • [28] In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
    Rajith K. R. Rajoli
    David J. Back
    Steve Rannard
    Caren Freel Meyers
    Charles Flexner
    Andrew Owen
    Marco Siccardi
    Clinical Pharmacokinetics, 2018, 57 : 255 - 266
  • [29] Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges
    Christopoulos, Katerina A.
    Hickey, Matthew D.
    Rana, Aadia
    CURRENT OPINION IN HIV AND AIDS, 2025, 20 (01) : 11 - 18
  • [30] In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
    Rajoli, Rajith K. R.
    Back, David J.
    Rannard, Steve
    Meyers, Caren Freel
    Flexner, Charles
    Owen, Andrew
    Siccardi, Marco
    CLINICAL PHARMACOKINETICS, 2018, 57 (02) : 255 - 266
12345